Trimer-Tag© Oncology

With our proprietary Trimer-Tag© technology platform, Clover has successfully designed and developed SCB-313 as a covalently-linked, native-like trimeric fusion protein which is structurally and functionally differentiated from the dimeric antibody-based structures and other native ligand-based candidates targeting this pathway. We believe SCB-313 has the potential to address the unmet global need for the treatment of intracavitary malignancies, including malignant ascites (MA), malignant pleural effusion (MPE), and peritoneal carcinomatosis (PC), as well as additional cancer indications.

Clover is exploring other targets in the TNFSF for immuno-oncology and immunology indications. We are currently conducting discovery programs evaluating trimeric fusion protein candidates targeting the 4-1BB pathway, a member of the TNFSF.